Feld R, Evans W K, Shepherd F A, Deboer G, Ottema B
Cancer Treat Rep. 1985 Feb;69(2):209-10.
Fourteen patients with measurable non-small cell lung cancer, who had not received prior chemotherapy, were treated with the anthracene derivative bisantrene. Although treatment was well tolerated, no antitumor activity was observed and all but two patients demonstrated disease progression before the third course of chemotherapy. We conclude that bisantrene does not have significant antitumor activity in non-small cell lung cancer.
14例未经前期化疗的可测量非小细胞肺癌患者接受了蒽衍生物双胺苯吖啶治疗。尽管治疗耐受性良好，但未观察到抗肿瘤活性，除2例患者外，所有患者在第三个化疗疗程前均出现疾病进展。我们得出结论，双胺苯吖啶在非小细胞肺癌中没有显著的抗肿瘤活性。
